Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy - Quiz - MDSpire

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

  • By

  • Miao Zhang

  • Haibin Yuan

  • Xindi Pan

  • Xian Li

  • Zichen Wang

  • Shuping Zhang

  • Zhigang Gu

  • Biao Hu

  • Xuedong Qu

  • Qian Wang

  • Xiangguo Gu

  • Bo Wang

  • Yu Cao

  • Guilin Mu

  • Guangbo Kang

  • Ario de Marco

  • Xiangshan Zhou

  • He Huang

  • June 10, 2026

  • 0 min

Share

Original Source(s)

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

  • by Miao Zhang, Haibin Yuan, Xindi Pan, Xian Li, Zichen Wang, Shuping Zhang, Zhigang Gu, Biao Hu, Xuedong Qu, Qian Wang, Xiangguo Gu, Bo Wang, Yu Cao, Guilin Mu, Guangbo Kang, Ario de Marco, Xiangshan Zhou, He Huang

  • June 10, 2026

Related Content

BCOR-CCNB3 fusion–positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up

Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney